A Phase I Study of BMS-354825 (Dasatinib) in Children With Recurrent/Refractory Solid Tumors or Imatinib Resistant Ph+ Leukemia (BMS Trial CA180038)

Trial Profile

A Phase I Study of BMS-354825 (Dasatinib) in Children With Recurrent/Refractory Solid Tumors or Imatinib Resistant Ph+ Leukemia (BMS Trial CA180038)

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jan 2013

At a glance

  • Drugs Dasatinib (Primary)
  • Indications Haematological malignancies; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 20 Feb 2009 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 08 Oct 2008 Status changed from recruiting to active, no longer recruiting, based on information from ClinicalTrials.gov.
    • 23 Jan 2007 Trial centres added.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top